Summary of Key Points Core Viewpoint - 康拓医疗 has experienced significant shareholder reductions in stock holdings, indicating potential shifts in investor confidence and ownership structure [1][2][3]. Group 1: Shareholder Reductions - 西安合赢企业管理咨询合伙企业 reduced its holdings by 595,537 shares, totaling approximately 18.35 million yuan [1]. - 董事朱海龙 reduced his holdings by 300,000 shares, amounting to about 8.70 million yuan [1]. - 董事吴栋 and 董事胡立功 reduced their holdings by 150,000 shares and 157,636 shares, respectively, totaling approximately 4.41 million yuan and 5.21 million yuan [1]. - Overall, the total reduction amounted to 1,203,173 shares, with a total value of approximately 36.65 million yuan [1]. Group 2: Shareholding Structure - As of June 9, 2025, 西安合赢企业管理咨询合伙企业 held 3,808,000 shares, representing 4.69% of the total shares [3]. - 董事朱海龙 directly holds 7,686,000 shares, which is 9.46% of the total shares [3]. - 董事吴栋 and 董事胡立功 hold 626,000 shares (0.77%) and 1,307,600 shares (1.61%), respectively [3]. Group 3: Initial Public Offering (IPO) Details - 康拓医疗 was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 18, 2021, with an initial public offering of 14.51 million shares, accounting for 25.01% of the total shares post-IPO [4]. - The IPO price was set at 17.34 yuan per share, raising a total of 252 million yuan, with a net amount of 208 million yuan after deducting issuance costs [4]. - The company initially planned to raise 523 million yuan, with 423 million yuan allocated for the development of implantable medical device products and 100 million yuan for working capital [4].